{"id":"ustekinumab-standard-dosage","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201835","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the p40 subunit, ustekinumab prevents the formation of the IL-12 and IL-23 heterodimers, which are essential for the activation of T helper 1 (Th1) and Th17 cells. This leads to a decrease in the production of pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17), which are involved in the pathogenesis of various inflammatory and autoimmune diseases.","oneSentence":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:28.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Moderate to severe Crohn's disease"},{"name":"Active psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT06520397","phase":"PHASE4","title":"Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-07-15","conditions":"Crohn Disease","enrollment":214},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide, Ustekinumab","enrollment":818},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT06956703","phase":"","title":"NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2022-12-12","conditions":"Gastro-Intestinal Disorder, Crohn Disease, Ulcerative Colitis","enrollment":240},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":906},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":839},{"nctId":"NCT06691061","phase":"","title":"The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis","status":"RECRUITING","sponsor":"Humanitas Clinical and Research Center","startDate":"2023-08-01","conditions":"Ulcerative Colitis (Disorder)","enrollment":450},{"nctId":"NCT04629196","phase":"PHASE4","title":"Induction Optimization With Stelara for Crohn's Disease","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Crohn Disease","enrollment":12},{"nctId":"NCT05861167","phase":"PHASE4","title":"SIIT Based on UST CDST in Patients With CD","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-06-01","conditions":"Crohn Disease","enrollment":140},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT05705856","phase":"","title":"Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-02-15","conditions":"Crohn Disease","enrollment":200},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT01090427","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Psoriasis","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ustekinumab - Standard Dosage","genericName":"Ustekinumab - Standard Dosage","companyName":"Humanitas Clinical and Research Center","companyId":"humanitas-clinical-and-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation. Used for Moderate to severe plaque psoriasis, Moderate to severe Crohn's disease, Active psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}